Biosimilar Stable Cell Pools

Accelerate your Antibody Development with Ready-to-use Stable Cell Pools

60+ biosimilar cell pools available
Validated for reference therapeutics
Custom antibodies/proteins expressing cell pools
High yields

Explore our Ready-to-use Stable Cell Pools for Therapeutic Antibody Development

Accelerate your path to therapeutic antibodies with our portfolio of well-characterized, high-expression stable cell pools.

Whether you are advancing biosimilar programs with gold-standard antibodies or driving the development of novel biologics, our off-the-shelf monoclonal cell pools are optimized for high-speed monoclonal development and bulk production!

Ask for your fast monoclonal development or for a bulk quantity of therapeutic antibody below !

Need to express your antibody or protein in a

Cell Line tailored to your needs?

Discover our custom cell line services

Featured Stable Cell Pools:

Each Stable cell pool is developed using our proprietary expression platform and quality-controlled
to ensure robust and consistent antibody production.

Name of therapeutics (pool)	Target	Isotype	Yield	Therapeutic Area
Cetuximab	hEGFR	IgG1	Between 5g/L and 10g/L	Oncology
Rituximab	MS4A1	IgG1	Between 5g/L and 10g/L	Immunotherapy
Ramucirumab	VEGFR-2	IgG1Kappa	Between 5g/L and 10g/L	Oncology
Infliximab	TNF-alpha	IgG1	Between 5g/L and 10g/L	Inflammation
Adalimumab	TNF-alpha	IgG1	Between 5g/L and 10g/L	Inflammation
Nivolumab	PD-1	IgG4	Between 5g/L and 10g/L	Immunotherapy
Bevacizumab	VEGF	IgG1	Between 5g/L and 10g/L	Oncology
Panitumumab	EGFR	IgG2-kappa	Between 5g/L and 10g/L	Oncology
Ustekinumab	Human IL-12 IL-23	IgG1	Between 5g/L and 10g/L	Inflammation
Ranibizumab	VEGF	FabG1	Between 5g/L and 10g/L	Oncology
Ipilimumab	CTLA-4	IgG2-kappa	Between 5g/L and 10g/L	Immunotherapy
Natalizumab	ITGA4, CD49d	IgG4-kappa	Between 5g/L and 10g/L	Inflammation
Daclizumab	IL2RA	IgG1-kappa	Between 5g/L and 10g/L	Inflammation
Palivizumab	RSV	IgG1-kappa	Between 5g/L and 10g/L	Virology
Belimumab	TNFSF13B, CD257	IgG1-lambda	Between 5g/L and 10g/L	Immunology
Denosumab	RANKL	IgG2Kappa	Between 5g/L and 10g/L	Developmental Biology

See full list below

Need to test the efficiency of your new drug candidate ?

Discover our biosimilar library

Why Choose our Stable Cell Pools?

High-yield & scalable CHO cell systems

Our cell pools are based on optimized CHO expression systems to ensure high productivity and seamless scalability, from lab-scale testing to large-scale bioproduction.

Expression of clinically validated monoclonal antibodies

Each stable cell pool expresses a monoclonal antibody referenced in clinical applications, ensuring biological relevance and reliable benchmarking for biosimilar development.

Quality controlled & sequence verified

All cell pools undergo strict QC procedures, including sequence verification, stability checks, and expression profiling to guarantee batch-to-batch consistency.

No royalties

ProteoGenix has selected parent royalty-free cell lines and owns its proprietary cell line, allowing you complete freedom for the future of your project.

Ideal for biosimilar R&D, validation, or early-stage production

Designed for flexibility, our cell pools are suited for analytical method development, comparative studies, and pilot-scale manufacturing in biosimilar pipelines.

FAQ

You can choose to acquire one or several high-performing pools, or proceed with monoclonal selection. In this case, deliverables include cells derived from the selected monoclonal clone (or multiple clones, if agreed), with the option to establish Master and Working Cell Banks. In addition, you will receive purified antibodies from the top 10 clones, accompanied by a comprehensive report detailing the development process, selection criteria, and comparative data across the leading monoclonal candidates.

📢 -40% on Recombinant Antibody Production. Available until November 16th on your first order. Code: RECAB40

Biosimilar Stable Cell Pools

Accelerate your Antibody Development with Ready-to-use Stable Cell Pools